Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis

被引：78
作者：
Fenaux, Pierre [1 ,2 ]
Kiladjian, Jean Jacques [2 ,3 ]
Platzbecker, Uwe [4 ,5 ]
机构：
[1] Hop St Louis, AP HP, Serv Hematol Seniors, F-75475 Paris, France
[2] Univ Paris Diderot, Dept Hematol, Paris, France
[3] Ctr Invest Cliniques, AP HP, Paris, France
[4] Leipzig Univ Hosp, Med Clin, Leipzig, Germany
[5] Leipzig Univ Hosp, Hematol & Cellular Therapy, Policlin 1, Leipzig, Germany
来源：
BLOOD | 2019年 / 133卷 / 08期
关键词：
TRANSFUSION-DEPENDENT PATIENTS; FC FUSION PROTEIN; LOWER-RISK MDS; SCORING SYSTEM; ERYTHROPOIESIS; RECEPTOR; BETA; SOTATERCEPT; PLACEBO; AZACITIDINE;
D O I：
10.1182/blood-2018-11-876888
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Anemia of lower-risk myelodysplastic syndromes (MDSs) and primary myelofibrosis (PMF) generally becomes resistant to available treatments, leading to red blood cell (RBC) transfusions, iron overload, shortened survival, and poor quality of life. The transforming growth factor-b superfamily, including activins and growth differentiation factors (GDFs), is aberrantly expressed in lower-risk MDSs and PMF. Luspatercept (and sotatercept), ligand traps that particularly inhibit GDF11, lead to RBC transfusion independence in 10% to 50% of lower-risk MDSs resistant to available treatments, and have started to be used in PMF.
引用
收藏
页码：790 / 794
页数：5
相关论文
共 57 条
  • [1] Sotatercept in patients with osteolytic lesions of multiple myeloma
    Abdulkadyrov, Kudrat M.
    Salogub, Galina N.
    Khuazheva, Nuriet K.
    Sherman, Matthew L.
    Laadem, Abderrahmane
    Barger, Rachel
    Knight, Robert
    Srinivasan, Shankar
    Terpos, Evangelos
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (06) : 814 - 823
  • [2] Agarwal Archana, 2016, Stem Cell Investig, V3, P5, DOI 10.3978/j.issn.2306-9759.2016.02.03
  • [3] Targeting the TGFβ signalling pathway in disease
    Akhurst, Rosemary J.
    Hata, Akiko
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (10) : 790 - 811
  • [4] Anemia and its relationship to clinical outcome in heart failure
    Anand, I
    McMurray, JJV
    Whitmore, J
    Warren, M
    Pham, A
    McCamish, MA
    Burton, PBJ
    [J]. CIRCULATION, 2004, 110 (02) : 149 - 154
  • [5] A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers
    Attie, Kenneth M.
    Allison, Mark J.
    McClure, Ty
    Boyd, Ingrid E.
    Wilson, Dawn M.
    Pearsall, Amelia E.
    Sherman, Matthew L.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (07) : 766 - 770
  • [6] Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
    Barbuil, Tiziano
    Tefferi, Ayalew
    Vannucchi, Alessandro M.
    Passamonti, Francesco
    Silvers, Richard T.
    Hoffman, Ronald
    Verstovsek, Srdan
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Hehlmann, Rudiger
    Reiter, Andreas
    Cervantes, Francisco
    Harrison, Claire
    Mc Mullin, Mary Frances
    Hasselbalch, Hans Carl
    Koschmieder, Steffen
    Marchetti, Monia
    Bacigalupo, Andrea
    Finazzil, Guido
    Kroeger, Nicolaus
    Griesshammer, Martin
    Birgegard, Gunnar
    Barosi, Giovanni
    [J]. LEUKEMIA, 2018, 32 (05) : 1057 - 1069
  • [7] miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling
    Bhagat, Tushar D.
    Zhou, Li
    Sokol, Lubomir
    Kessel, Rachel
    Caceres, Gisela
    Gundabolu, Krishna
    Tamari, Roni
    Gordon, Shanisha
    Mantzaris, Ioannis
    Jodlowski, Tomasz
    Yu, Yiting
    Jing, Xiaohong
    Polineni, Rahul
    Bhatia, Kavi
    Pellagatti, Andrea
    Boultwood, Jacqueline
    Kambhampati, Suman
    Steidl, Ulrich
    Stein, Cy
    Ju, Wenjun
    Liu, Gang
    Kenny, Paraic
    List, Alan
    Bitzer, Markus
    Verma, Amit
    [J]. BLOOD, 2013, 121 (15) : 2875 - 2881
  • [8] Cappellini MD, 2018, P AM SOC HEM ANN M 1
  • [9] An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin
    Carrancio, Soraya
    Markovics, Jennifer
    Wong, Piu
    Leisten, Jim
    Castiglioni, Paola
    Groza, Matthew C.
    Raymon, Heather K.
    Heise, Carla
    Daniel, Tom
    Chopra, Rajesh
    Sung, Victoria
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (06) : 870 - 882
  • [10] Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis
    Ceglia, Ilaria
    Dueck, Amylou C.
    Masiello, Francesca
    Martelli, Fabrizio
    He, Wu
    Federici, Giulia
    Petricoin, Emanuel F., III
    Zeuner, Ann
    Iancu-Rubin, Camelia
    Weinberg, Rona
    Hoffman, Ronald
    Mascarenhas, John
    Migliaccio, Anna Rita
    [J]. EXPERIMENTAL HEMATOLOGY, 2016, 44 (12) : 1138 - 1155
123456